Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines
Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%;.
The FDA has accepted for priority review the supplemental new drug application for belzutifan to treat adults with advanced RCC who previously received immune checkpoint and anti-angiogenic therapies.